Active Ingredient(s): Basiliximab
FDA Approved: * May 12, 1998
Pharm Company: * NOVARTIS
Category: Immunosuppressive

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. Contents 1 Uses 2 Mechanism of action 3 Chemistry 4 History 5 See also 6 References and notes Uses Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with o... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Simulect 20 mg/5ml Intravenous Injection, Powder, for Solution
NDC: 0078-0331
Novartis Pharmaceuticals Corporation
Simulect 10 mg/2.5ml Intravenous Injection, Powder, for Solution
NDC: 0078-0393
Novartis Pharmaceuticals Corporation